{"entity":{"id":"nct06500676","kind":"trial","name":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","aka":[],"tldr":"A phase 1/2 trial of GFH375 in advanced solid tumours, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.","summary":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations is a phase 1/2 interventional study registered as NCT06500676 by Genfleet Therapeutics (Shanghai) Inc., with 407 participants planned, started 2024-07-09 and due to reach its primary completion in 2028-07-31. Interventions recorded: GFH375.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06500676","url":"https://clinicaltrials.gov/study/NCT06500676"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["gfh375"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06500676","phase":"1/2","setting":"An Open-Label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GFH375 in Patients With KRAS G12D Mutant Advanced Solid Tumors","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","enrolled":407,"outcomes":[]},"route":"/trials/nct06500676/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"gfh375","kind":"drug","name":"GFH375","route":"/drugs/gfh375/"}]}}